Skip to main content
Search

Amit M. Oza

1 related articles

Subscribe to updates
  1. Cancer

    The Evolving Role of Immunotherapy in Ovarian Cancer: From Empirical Use Toward Biology-Driven Combination and Precision Strategies

    This review synthesizes the clinical evidence and resistance mechanisms for immunotherapy in ovarian cancer, noting that single-agent immune checkpoint inhibitors achieve objective response rates generally below 15% in recurrent disease, that the clearest added benefit appears in chemotherapy-based combinations for PD-L1-positive platinum-resistant disease (e.g., in ENGOT-ov65/KEYNOTE-B96, median overall survival 18.2 vs 14.0 months in the CPS >=1 population, HR 0.

You’re all caught up